The Peptidoglycan Biosynthesis Process in Bacteria

Peptidoglycan biosynthesis is a multi-stage assembly line that begins inside the bacterial cell, crosses through the membrane, and finishes on the cell’s exterior, where individual building blocks are stitched into a mesh-like shell that surrounds the entire organism. This shell, called the sacculus, consists of sugar chains cross-linked by short peptides, forming a lattice that gives bacteria their characteristic shapes and prevents them from bursting under internal pressure.¹ The process is tightly coordinated, essential for survival, and the target of some of the most widely used antibiotics in medicine.

Building the Precursor Inside the Cell

The first phase of peptidoglycan biosynthesis takes place entirely in the cytoplasm. The goal is to construct a sugar-peptide unit called UDP-MurNAc-pentapeptide, which serves as the monomeric raw material for everything that follows. Six enzymes, collectively known as the Mur enzymes (MurA through MurF), carry out this work in sequence.²

The process starts with a common sugar nucleotide, UDP-GlcNAc, which bacteria already produce for other metabolic purposes. MurA and MurB convert it into UDP-MurNAc by adding a lactyl group, creating the sugar that is unique to peptidoglycan. Then four ligase enzymes attach amino acids one at a time onto that sugar. MurC adds L-alanine, MurD adds D-glutamic acid, MurE adds a diamino acid (usually either meso-diaminopimelic acid or L-lysine, depending on the species), and MurF adds a D-Ala-D-Ala dipeptide to cap off the chain.³ The result is a sugar carrying a five-amino-acid tail: the pentapeptide precursor that will eventually become the cross-linkable arm of the finished wall.

Every one of these six enzymes is essential. Knock out any single Mur enzyme and the bacterium cannot build its wall, which makes this pathway an appealing set of drug targets.⁴

Attaching the Precursor to the Membrane

The cytoplasmic precursor is water-soluble, but it needs to cross the oily interior of the cell membrane to reach the outside. Bacteria solve this by attaching the precursor to a lipid carrier embedded in the membrane, a molecule called undecaprenyl phosphate. The enzyme MraY catalyzes this first membrane-associated step, transferring the phospho-MurNAc-pentapeptide onto the lipid carrier to produce a molecule called Lipid I.⁵

A second enzyme, MurG, then adds the other sugar component, GlcNAc, onto Lipid I. The product is Lipid II, the complete disaccharide-pentapeptide unit tethered to the membrane lipid. Lipid II is the final monomeric building block of peptidoglycan, carrying one copy of everything needed for both the sugar backbone and the peptide cross-link of the finished wall.⁵ Despite its central importance, Lipid II is present in vanishingly small amounts at any given moment, making it a bottleneck and, as we will see, an attractive antibiotic target.⁶

Flipping Lipid II Across the Membrane

Lipid II is assembled on the inner face of the membrane, but it needs to end up on the outer face where polymerization happens. For years, the identity of the protein responsible for flipping Lipid II across the membrane was one of the biggest open questions in bacterial cell biology. That changed when researchers demonstrated that a protein called MurJ, a member of the MOP exporter family, is the Lipid II flippase in Escherichia coli.⁷

MurJ works through an alternating-access mechanism, opening first to one side of the membrane, then the other, and its activity depends on the electrical charge difference across the membrane.⁸ The picture is not entirely simple, though. In Bacillus subtilis, a second, unrelated protein called Amj can substitute for MurJ, suggesting that some bacteria carry backup flippases for this critical step.⁹ Regardless of which protein does the job, the outcome is the same: Lipid II arrives on the outer face of the membrane, ready for the final construction phase.

Polymerization and Cross-Linking Outside the Cell

Once Lipid II reaches the outside, two enzymatic activities turn individual units into a continuous wall. Glycosyltransferases link the sugar portions of neighboring Lipid II molecules together, forming long glycan strands. Transpeptidases then connect the peptide side chains of adjacent strands to each other, creating the cross-linked mesh that gives peptidoglycan its mechanical strength.¹⁰

The transpeptidation step has received enormous attention because the enzymes responsible, the penicillin-binding proteins (PBPs), are the targets of beta-lactam antibiotics like penicillin and cephalosporins.¹¹ But PBPs are not the only cross-linkers. A second class of enzymes called LD-transpeptidases creates a chemically distinct type of cross-link. For decades these were considered minor players, but accumulating evidence shows they contribute to cell wall adaptation under stress, help maintain outer membrane stability, and in some species may be the dominant cross-linking enzymes.¹² Recent work has expanded the known chemistry of LD-transpeptidases further, identifying non-canonical linkage types that broaden the structural repertoire of the finished wall.¹³

Structural Differences Between Species

Although the overall architecture of peptidoglycan is conserved across bacteria, the details vary. The sugar backbone is essentially the same everywhere, but the peptide stem and the way strands are cross-linked differ from species to species. The amino acid at the third position of the stem peptide is a key point of variation: most Gram-negative bacteria and Bacilli use meso-diaminopimelic acid, while most Gram-positive cocci use L-lysine.¹⁴

Cross-linking also diverges. In most Gram-negative bacteria, the peptide stems connect directly to each other. In many Gram-positive organisms, a short bridge of additional amino acids sits between the two stems. Staphylococcus aureus, for instance, has a pentaglycine bridge. These structural variations are one reason why certain antibiotics work better against Gram-positive or Gram-negative bacteria, and they form the basis of a classification system for peptidoglycan types that has been in use for over 50 years.¹⁴

How Bacteria Coordinate Wall Synthesis During Growth and Division

A bacterium’s wall is not built once and left alone. As the cell grows longer, new peptidoglycan must be inserted into the existing shell without creating gaps that would let the cell burst. Rod-shaped bacteria manage this through a protein complex called the elongasome, organized around MreB, a protein related to the structural protein actin found in animal cells. MreB forms filaments along the inner surface of the membrane and guides peptidoglycan synthesis machinery to the right locations along the cell’s length.¹⁵ MreB also interacts with other membrane proteins like RodZ and MreC/D to coordinate the process and respond to environmental signals.¹⁶

When the cell is ready to divide, a separate machine takes over. The divisome, organized by the tubulin-like protein FtsZ, assembles at the middle of the cell and builds a peptidoglycan septum that eventually splits the cell in two. FtsZ polymers form a ring and recruit the septal wall synthesis enzymes FtsW and FtsI, which are controlled by a regulatory subcomplex and an activator protein called FtsN.¹⁷ In E. coli, treadmilling FtsZ polymers drive the movement of septal synthesis enzymes around the division site, and FtsZ is essential for initiating constriction but becomes dispensable as constriction progresses.¹⁸

Remodeling, Recycling, and the Balance of Construction and Demolition

Building new wall is only half the story. Bacteria simultaneously break down portions of their existing peptidoglycan using hydrolase enzymes, sometimes called autolysins. Three main classes of hydrolases each cut a different bond in the peptidoglycan structure: amidases cut between the sugar and the peptide, glycosidases cut between the sugars, and peptidases cut within the peptide chains.¹⁹ These enzymes must be carefully regulated; too much activity could be fatal, but too little would prevent daughter cells from separating after division. In Staphylococcus aureus, autolysin-mediated hydrolysis is also required to properly display surface proteins, including virulence factors like protein A and fibronectin-binding proteins.²⁰

One way bacteria fine-tune autolysin activity involves the type of cross-link in the wall. Experiments in Vibrio cholerae showed that increasing the proportion of LD-cross-links significantly repressed the activity of lytic transglycosylases, a major class of autolytic glycosidases. The effect was dose-dependent: the more LD-cross-links in the substrate, the less the enzymes could cut it.²¹

The fragments released during wall turnover do not go to waste. Bacteria actively reclaim them through dedicated transport systems. E. coli is estimated to break down roughly a third of its cell wall per generation, yet loses only about 0 to 5% of diaminopimelic acid, a peptidoglycan-specific amino acid, indicating highly efficient recycling. At least two transport systems, the permease AmpG and the Opp transporter working with a periplasmic binding protein called MppA, bring fragments back into the cytoplasm for reuse.²²

Why the Immune System Pays Attention to Peptidoglycan

Because peptidoglycan is unique to bacteria, animal immune systems have evolved to detect it as a sign of infection. The enzyme lysozyme, abundant in tears, saliva, and mucus, attacks the glycan backbone directly. But lysozyme does more than just kill bacteria: even when it does not destroy the cell, it releases enough peptidoglycan fragments to trigger immune signaling.²³ Those fragments are sensed by cytoplasmic receptors called NOD1 and NOD2, which activate inflammatory pathways and stimulate the production of cytokines and antimicrobial molecules.

In the case of Streptococcus pneumoniae colonization in mice, the sequence plays out as follows: professional immune cells engulf the bacteria, lysozyme digests the peptidoglycan, NOD2 senses the products, and the cells release a chemokine that recruits additional monocytes and macrophages for clearance. The adaptive immune response, measured by antibody production, also depended on this lysozyme-NOD2 pathway.²⁴

This immune recognition creates a selective pressure on pathogenic bacteria. Many mucosal pathogens modify the chemical groups around the lysozyme cleavage site in their peptidoglycan to resist degradation and avoid releasing the proinflammatory fragments that would give them away.²⁵ Helicobacter pylori uses two modification enzymes, PgdA (an N-deacetylase) and PatA (an O-acetyltransferase), that work synergistically to confer lysozyme tolerance.²⁶ Staphylococcus aureus relies on the O-acetyltransferase OatA as its primary defense against lysozyme; mutants lacking OatA lose O-acetylation of their muramic acid residues and become highly susceptible.²⁷

Antibiotics That Target the Pathway

Peptidoglycan biosynthesis is one of the most productive antibiotic target spaces in medicine, precisely because every step is essential and the entire pathway is absent from human cells. Different antibiotic classes interrupt different stages:

Cytoplasmic steps: Fosfomycin inhibits MurA, the very first committed enzyme. The Mur ligases (MurC through MurF) and upstream enzymes like GlmS, GlmM, and GlmU are all being explored as targets for next-generation drugs.
Lipid II itself: Vancomycin and several naturally occurring antimicrobial peptides called lantibiotics bind directly to Lipid II, sequestering it so it cannot be polymerized.⁶
Transpeptidation: Beta-lactams, the most widely prescribed antibiotic class, are covalent inhibitors of PBPs. They mimic the D-Ala-D-Ala end of the peptide stem and permanently block the transpeptidase active site, preventing cross-linking.¹¹

Each of these drugs exploits the same fundamental vulnerability: block any one step and the cell wall fails, typically leading to lysis and death. The challenge is resistance. Bacteria evolve altered PBPs that no longer bind beta-lactams tightly, produce beta-lactamase enzymes that destroy the drugs before they reach their targets, or switch to LD-transpeptidase-mediated cross-linking that bypasses PBPs entirely.¹²

Bacteria That Abandon the Wall Entirely

Given how central peptidoglycan is to bacterial life, it may come as a surprise that some bacteria can survive without it. Under certain conditions, bacteria can transition into so-called L-forms, wall-deficient cells that proliferate using a completely different mechanism. Instead of the orderly FtsZ-based division used by walled cells, L-forms divide through membrane blebbing and scission driven entirely by an excess of membrane synthesis relative to cell volume.²⁸

Antibiotics that block cell wall precursor synthesis, such as fosfomycin, can efficiently trigger the L-form switch without requiring any genetic change. However, sustaining L-form growth does require genetic adaptations: one class of mutations drives excess membrane production (either by activating fatty acid synthesis or by shutting down peptidoglycan precursor pathways), while a second class counteracts the oxidative stress that wall-deficient cells apparently experience due to metabolic imbalance.²⁹ L-forms are more than a laboratory curiosity; they have been proposed as potential contributors to chronic and recurrent infections, since they are invisible to antibiotics that target the cell wall.

Phage Lysins as New Weapons Against the Wall

Bacteriophages, the viruses that infect bacteria, have been breaking open peptidoglycan for billions of years. At the end of their replication cycle, phages produce enzymes called endolysins that hydrolyze the host’s cell wall from inside, releasing a new crop of viral particles. Researchers are now repurposing these enzymes as antimicrobials. Endolysins kill bacteria rapidly, target them with high specificity, and face low rates of resistance development, making them appealing alternatives in an era of rising antibiotic resistance.³⁰

Several endolysins targeting Gram-positive bacteria are currently in clinical trials. The evidence from preclinical studies, however, suggests that endolysin monotherapy produces inconsistent results, and their greatest therapeutic potential appears to be in combination with standard antibiotics, except in situations where treatment can be applied locally or topically.³¹ Gram-negative bacteria present an additional engineering challenge because their outer membrane shields the peptidoglycan from externally applied endolysins. Active research is exploring modified endolysins and combinations with membrane-disrupting peptides to overcome this barrier.³²

1
PubMed Central. Compositional analysis of bacterial peptidoglycan: insights from peptidoglycomics into structure and function
2
PubMed. Reconstitution of the peptidoglycan cytoplasmic precursor biosynthetic pathway in cell-free system and rapid screening of antisense oligonucleotides for Mur enzymes
3
FEMS Microbiology Reviews. Cytoplasmic steps of peptidoglycan biosynthesis
4
PubMed Central. Development of a one-pot assay for screening and identification of Mur pathway inhibitors in Mycobacterium tuberculosis
5
PubMed Central. The Bacterial Cell Wall: From Lipid II Flipping to Polymerization
6
PubMed. Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics
7
PubMed Central. Bacterial cell wall. MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis
8
PubMed Central. The bacterial lipid II flippase MurJ functions by an alternating-access mechanism
9
PubMed Central. MurJ and a novel lipid II flippase are required for cell wall biogenesis in Bacillus subtilis
10
PubMed Central. Peptidoglycan: Structure, Synthesis, and Regulation
11
PubMed Central. β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates
12
PubMed. LD-transpeptidases: the great unknown among the peptidoglycan cross-linkers
13
PubMed. LD-transpeptidation in bacterial cell walls: biochemical principles and functional diversity
14
FEMS Microbiology Reviews. Peptidoglycan structure and architecture
15
PubMed Central. MreB filaments in the elongasome modulate E. coli membrane curvature
16
PubMed Central. MreB: unraveling the molecular mechanisms of bacterial shape, division, and environmental adaptation
17
PubMed Central. An Updated Model of the Divisome: Regulation of the Septal Peptidoglycan Synthesis Machinery by the Divisome
18
PubMed Central. FtsZ-mediated spatial-temporal control over septal cell wall synthesis
19
PubMed Central. Cell Wall Hydrolases in Bacteria: Insight on the Diversity of Cell Wall Amidases, Glycosidases and Peptidases Toward Peptidoglycan
20
PubMed Central. Autolysin-mediated peptidoglycan hydrolysis is required for the surface display of Staphylococcus aureus cell wall-anchored proteins
21
Nature Communications. Control of bacterial cell wall autolysins by peptidoglycan crosslinking mode
22
PubMed Central. Escherichia coli utilizes multiple peptidoglycan recycling permeases with distinct strategies of recycling
23
PLOS Pathogens. From bacterial killing to immune modulation: Recent insights into the functions of lysozyme
24
JCI Insight. Nod2 sensing of lysozyme-digested peptidoglycan promotes macrophage recruitment and clearance of S. pneumoniae colonization in mice
25
PubMed Central. Modifications to the peptidoglycan backbone help bacteria to establish infection
26
PubMed Central. Helicobacter pylori peptidoglycan modifications confer lysozyme resistance and contribute to survival in the host
27
PubMed. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus
28
PubMed Central. Cell wall-deficient, L-form bacteria in the 21st century: a personal perspective
29
PubMed Central. L-form bacteria, chronic diseases and the origins of life
30
PubMed Central. Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria
31
PubMed Central. Clinical implementation of endolysins targeting gram-positive bacteria points toward a combination strategy with standard-of-care antibiotics: a selective review
32
PubMed Central. Endolysins and membrane-active peptides: innovative engineering strategies against gram-negative bacteria